James Jarrett, PhD

Senior Director, HEOR
Gilead Sciences, Inc.

Poster(s):

• (251) Preference for twice-yearly injections vs daily oral pills for HIV PrEP in cisgender men, transgender women, transgender men, and gender nonbinary people enrolled in PURPOSE 2
  Wednesday, October 29, 2025

• (253) Treatment switch among United States Medicare beneficiaries with human immunodeficiency virus
  Wednesday, October 29, 2025

• (254) Antiretroviral therapy persistence among treatment-experienced people with human immunodeficiency virus and mental health disorders in the United States
  Wednesday, October 29, 2025